We are dedicated to preventing and curing Multiple Sclerosis. In an aggressive campaign to develop therapies that promote repair and regeneration of myelin in MS, we have assembled teams of superb researchers whose collaboration, productivity and determination has led to important discoveries on the path to delivering regenerative treatments to people with MS. Resources for this work come from grants through the National Institutes of Health, The National Multiple Sclerosis Society, and, most crucially, from individual donors like you. The greater our resources, the faster our pace at making discoveries that make a meaningful difference. We welcome the opportunity to discuss our efforts with you in detail.

Donate Now

Research and Discoveries

Developed -

  • new MRI and molecular imaging techniques to define inflammation, injury and repair in multiple sclerosis
  • a new theory of brain injury in multiple sclerosis where global inflammation results in irreversible injury to neurons and axons

Identified -

  • a novel molecular target of multiple sclerosis that when inhabited in animal models, promotes regeneration of myelin and restoration of function
  • a major molecular pathway in MS that limits normal regeneration of the myelin sheath

Are Collaborating With -

  • Cornell University in Ithaca, Rockefeller University, and Memorial Sloan Kettering Cancer Center, to develop "neuroprotective agents" to shied MS patients against the more advanced second stage of neurodegeneration
  • MS research centers across the country in major multi-center studies that promise to lead to improved understanding of MS at varied stages and provide keys to treatments -

  • The International Multiple Sclerosis Genetics Consortium on a comprehensive assessment of genetic influences on MS. Once complete, this project will establish an atlas of common genetic variations that affect susceptibility of MS. In addition, the research will identify novel disease candidate genes, pathways and networks, leading to testable hypotheses as to which genes contribute to susceptibility to Multiple Sclerosis.

The goal of these studies is to design and improve clinical trials so they can be tailored for the many subgroups of Multiple Sclerosis. Through these kinds of focused clinical trials, it will be possible to better contour individual treatment based on the unique progression of the disease in each patient.

Back to Top